Assessing the robustness of COVID-19 vaccine efficacy trials: systematic review and meta-analysis, January 2023

ConclusionsThis was the largest study on trial robustness to date. Robustness of COVID-19 VE trials increased with sample size and varied considerably across several other important trial characteristics. The FI and FQ are valuable complementary parameters for the interpretation of trial results and should be reported alongside established trial outcome measures.

Source: Eurosurveillance - June 1, 2023 Category: Infectious Diseases Authors: Thi Ngoc Anh Hoang, Ha-Linh Quach, Van Ngoc Hoang, Van Thien Tran, Quang Thai Pham and Florian Vogt Source Type: research